Passage Bio Q3 EPS $(0.49) Misses $(0.46) Estimate
Portfolio Pulse from Benzinga Newsdesk
Passage Bio (NASDAQ:PASG) reported a Q3 loss of $(0.49) per share, missing the consensus estimate of $(0.46) by 6.52%. The reported loss is the same as the loss reported in the same period last year.
November 13, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Passage Bio reported a Q3 EPS loss of $(0.49), which did not meet the expected $(0.46) estimate, showing no improvement from the previous year.
Missing earnings estimates can negatively impact investor sentiment and stock price in the short term. Since the performance is unchanged from the previous year, it may raise concerns about the company's growth prospects.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100